How to buy Australian Clinical Labs (ACL) shares in Australia
Learn how to easily invest in Australian Clinical Labs shares.
Australian Clinical Labs is a diagnostics & research business based in Australia. Australian Clinical Labs shares (ACL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Australian Clinical Labs has a trailing 12-month revenue of around $697.1 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Australian Clinical Labs
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Australian Clinical Labs. Find the share by name or ticker symbol: ACL. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Australian Clinical Labs reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Australian Clinical Labs. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
What's in this guide?
- Australian Clinical Labs key stats
- Compare share trading platforms
- Is Australian Clinical Labs stock a buy or sell?
- Australian Clinical Labs performance over time
- Are Australian Clinical Labs shares over-valued?
- Australian Clinical Labs's financials
- How volatile are Australian Clinical Labs shares?
- Does Australian Clinical Labs pay a dividend?
- Other common questions
Australian Clinical Labs stock price (ASX:ACL)Use our graph to track the performance of ACL stocks over time.
Australian Clinical Labs shares at a glance
|52-week range||$2.47 - $3.7053|
|50-day moving average||$2.6916|
|200-day moving average||$3.1766|
|Dividend yield||$0.14 (5.36%)|
|Earnings per share (TTM)||$0.18|
Compare share trading platforms
Is it a good time to buy Australian Clinical Labs stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Australian Clinical Labs price performance over time
|1 week (2023-11-30)||9.54%|
|1 month (2023-11-10)||7.49%|
|3 months (2023-09-08)||-4.65%|
|6 months (2023-06-09)||-14.07%|
|1 year (2022-12-09)||-7.42%|
|2 years (2021-12-10)||-38.01%|
Is Australian Clinical Labs under- or over-valued?
Valuing Australian Clinical Labs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Australian Clinical Labs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Australian Clinical Labs's P/E ratio
Australian Clinical Labs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Australian Clinical Labs shares trade at around 14x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Australian Clinical Labs's EBITDA
Australian Clinical Labs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $78.5 million (£0.0 million).
The EBITDA is a measure of a Australian Clinical Labs's overall financial performance and is widely used to measure stock profitability.
Australian Clinical Labs financials
|Revenue TTM||$697.1 million|
|Operating margin TTM||8.69%|
|Gross profit TTM||$250.4 million|
|Return on assets TTM||6.63%|
|Return on equity TTM||17.79%|
|Market capitalisation||$526.8 million|
TTM: trailing 12 months
Australian Clinical Labs share dividends
Dividend payout ratio: 107.69% of net profits
Recently Australian Clinical Labs has paid out, on average, around 107.69% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.36% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Australian Clinical Labs shareholders could enjoy a 5.36% return on their shares, in the form of dividend payments. In Australian Clinical Labs's case, that would currently equate to about A$0.14 per share.
Australian Clinical Labs's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 14 September 2023 (the "ex-dividend date").
Australian Clinical Labs share price volatility
Over the last 12 months, Australian Clinical Labs's shares have ranged in value from as little as $2.47 up to $3.7053. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Australian Clinical Labs's is 1.153. This would suggest that Australian Clinical Labs's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).
Australian Clinical Labs overview
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. Australian Clinical Labs Limited was incorporated in 2020 and is headquartered in Clayton, Australia.
Stocks similar to Australian Clinical Labs
Australian Clinical Labs in the news
Frequently asked questions
More guides on Finder
Shein IPO: How to invest in the Shein IPO
What you need to know about investing in Shein from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Tiger Brokers review for Australians
If you're thinking of trading stocks with Tiger Brokers, check out our review of this online broker's fees, safety and pros and cons first.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Caltex Australia shares
Steps to owning and managing Caltex Australia shares from .
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Dec 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia for 2023
Follow these tips to find the best share trading platform for you.
Ask an Expert